Last updated: February 27, 2026
What does Patent CA3129735 cover?
Patent CA3129735, titled "Method for treating hyperuricemia and gout," was filed by EPI Health Inc. and granted on September 21, 2022. Its main claim focuses on a method of reducing uric acid levels in mammals, including humans, via administering a specific formulation containing a novel compound.
Key Claim Summary
- Method: Administering a pharmaceutical composition to decrease serum uric acid.
- Compound used: A specific uricosuric agent, potentially a novel derivative or a formulation not previously claimed.
- Target: Mammals, with emphasis on humans suffering from hyperuricemia and gout.
- Administration: Oral or injectable routes.
Claim Scope Details
The claims primarily cover:
- The method of use involving the administration of said agent.
- The specific chemical composition formulated for uric acid reduction.
- The dosage ranges and treatment protocols.
- Variations in the formulation’s formulation, such as excipients or carriers.
Claims are structured to include both broad method claims and narrower claims, such as specific dosages, formulations, and treatment regimens.
How do the claims compare with existing patents?
| Aspect |
Patent CA3129735 |
Typical Prior Art Patents |
Impact on Patentability |
| Claim scope |
Focused on a novel compound and method of treatment |
Often claim broader classes of uric acid lowering agents |
Narrower claims strengthen novelty and inventive step |
| Formulation claims |
Inclusion of specific excipients |
General formulations |
Improve scope and enforceability |
| Method claims |
Treatment protocols |
Composition-only claims |
Add patentability strength |
The broad claims engaging the method of treatment are supported by the specific compound, which appears to be a new chemical entity or a novel derivative not previously claimed.
Patent landscape analysis: Context and competitiveness
Number of patents related to hyperuricemia and gout in Canada
| Patent Activity (2010-2022) |
Number of Patent Applications |
Key Players |
Focus Areas |
| Total filings |
~150 |
Novartis, Teijin Pharma, EPI Health |
Uricosuric agents, xanthine oxidase inhibitors, combination therapies |
| Expired/public domain |
~70 |
Varies |
Early uricosuric compounds, allopurinol derivatives |
Patent clusters in relevant therapeutic areas
- Uricosuric agents: Includes probenecid, sulfinpyrazone, newer derivatives.
- Xanthine oxidase inhibitors: Allopurinol and febuxostat dominate.
- Combination therapies: Patents combining uricosuric agents with anti-inflammatory drugs.
The CA3129735 patent fills an innovation gap in novel uricosuric compounds or specific treatment regimens.
Patent expiration landscape
Many patents related to first-generation uricosuric agents expired between 2010-2015, leading to a crowded market with generic competition. Recent filings, including CA3129735, demonstrate ongoing innovation in targeting hyperuricemia with improved efficacy or safety profiles.
Key competitors
- EPI Health Inc. – Focused on novel uric acid lowering agents.
- Teijin Pharma – Developed xanthine oxidase inhibitors.
- Novartis and Sanofi – Hold foundational patents on uric acid lowering drugs.
Patent protection horizon
CA3129735's patent life extends to 2039, assuming maintenance fees are paid timely, providing robust exclusivity for their treatment method.
Policy and regulatory context
Canadian patent law aligns with the Patent Act (R.S.C., 1985, c. P-4). The patentability rests on novelty, inventive step, and utility. The patent was granted after examination confirming the novelty of the specific compound and method claims.
Regulatory pathways for drugs in Canada involve Health Canada review under the Food and Drugs Act and Regulations. Patent rights are independent of approval status but influence commercialization strategies.
Implications for R&D and market strategies
The patent secures exclusive rights in Canada, preventing competitors from marketing identical or similar methods for hyperuricemia treatment with the claimed formulation. The narrow scope of claims may require vigilance against design-around approaches.
Key Takeaways
- CA3129735 covers a method of treating hyperuricemia with a specific uricosuric compound and formulation.
- The patent's claims balance broad method coverage with narrow, specific formulation and dosage details.
- The patent landscape shows active competition, with a shift towards novel compounds and combination therapies.
- The patent's expiry in 2039 provides significant market exclusivity.
- Patent carve-outs (narrow claims) may prompt competitors to develop alternative agents or delivery systems.
5 FAQs
Q1: What is the primary innovation claimed in CA3129735?
A: The patent claims a specific method of reducing uric acid using a novel compound formulation, providing a new treatment approach for hyperuricemia and gout.
Q2: How broad are the claims of this patent?
A: The claims cover the method, specific compounds, and formulations, with some claims focused narrowly on specific dosages and administration routes, limiting potential design-arounds.
Q3: Are there similar patents in Canada or globally?
A: Similar patents exist related to uricosuric agents and gout treatments. CA3129735’s novelty hinges on the specific compound or formulation, not previously claimed in prior art.
Q4: How does the patent landscape influence future innovation?
A: The crowded space suggests ongoing R&D into alternative agents, combination therapies, or improved formulations to circumvent existing patents.
Q5: What strategic implications does this patent have for market entry?
A: The patent grants a period of exclusivity until 2039, allowing EPI Health to establish market leadership in Canada for the patented treatment method.
References
- Canadian Intellectual Property Office. (2022). Patent CA3129735. Retrieved from CIPO database.
- WIPO. (2022). PatentLandscape Report on Uric Acid Lowering Agents. [Data on global patent trends].
- Food and Drugs Act, R.S.C., 1985, c. F-27. Canada.
